|Year : 2018 | Volume
| Issue : 3 | Page : 111-112
The metabolic syndrome and menopause
Ranu Patni1, Annil Mahajan2
1 Senior Consultant Gynaecological Oncosurgeon, EHCC Hospital and Prayaas Clinic, Jaipur, Rajasthan, India
2 Professor & HOD, Department of Medicine, Government Medical College, Jammu, Jammu and Kashmir, India
|Date of Web Publication||21-Sep-2018|
Professor & HOD, Department of Medicine, Government Medical College, Jammu, Jammu and Kashmir
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Patni R, Mahajan A. The metabolic syndrome and menopause. J Mid-life Health 2018;9:111-2
Recently, a national English daily newspaper published a report stating that by the year 2050, India's population will hit 1.7 billion, but its child population (those below 15 years of age) is projected to come down by 20%. Furthermore, the population of Indians above 65 will increase by almost three times.
This will probably lead to a boost in diseases associated with aging. Unhealthy lifestyle practices which are becoming more prevalent in the current generation will further compromise the quality of life. Metabolic syndrome and its consequences will contribute significantly to this disease profile.
Metabolic syndrome is basically a lifestyle disease. It is a constellation of metabolic abnormalities that confer an increased risk of cardiovascular disease and diabetes mellitus.
The WHO defines metabolic syndrome as insulin resistance (IR) along with any two of the following criteria:
- Abdominal/central obesity: Waist-to-hip ratio: >0.90 (men), >0.85 (women), or body mass index >30
- Hypertriglyceridemia: ≥150 mg/dL
- Low high-density lipoprotein (HDL) cholesterol: <35 mg/dl for men and <39 mg/dL for women
- High blood pressure: ≥140/90 mmHg or documented use of antihypertensive therapy
- High fasting glucose: Impaired glucose tolerance, impaired fasting glucose, IR, or diabetes
- Microalbuminuria: Urinary albumin-to-creatinine ratio: 30 mg/g, or albumin excretion rate: 20 μg/min.
Epidemiologically, it has been seen that the prevalence of metabolic syndrome increases with age. Sedentary lifestyle with increasing industrialization and urbanization is leading to an increase in obesity and metabolic syndrome. Increased waist circumference is most strongly related to IR and cardiovascular diseases. Increase in waist circumference is found more commonly in women.
Risk factors for metabolic syndrome include obesity, body fat distribution, physical inactivity, excess caloric intake, unhealthy dietary habits, exposure to certain medications such as antipsychotics, family history, socioeconomic factors, and low Vitamin D levels.
Apart from cardiovascular disease and type 2 diabetes mellitus, metabolic syndrome is also said to increase the risk of nonalcoholic fatty liver disease, hyperuricemia, polycystic ovarian syndrome, obstructive sleep apnea, etc.
It is estimated that almost 20%–30% of the middle-aged population are affected by this syndrome. Incidence varies from 8% to 24% in males  and from 7% to 46% in females. Many cross-sectional studies have shown an increased risk of metabolic syndrome in postmenopausal women, which varies from 32.6% to 41.5%.
Menopause, which is a sex steroid hormone-depleted state, increases the vulnerability to disease in hormone-responsive tissues such as bone, brain, and the cardiovascular system. This leads to a compromised quality of life. Menopause is associated with redistribution of body weight and weight gain in a majority of women. Weight gain and obesity largely drive the increased prevalence of metabolic syndrome in postmenopausal women. Menopause is considered a predictor of metabolic syndrome independent of women's age. The simultaneous occurrence of IR and obesity (especially visceral adiposity) is the most detrimental for metabolic health. This is also associated with oxidative stress, inflammatory and prothrombotic processes, as well as postmenopausal alterations in adipocytokine production. Chedraui et al. showed that in women with metabolic syndrome, lower adiponectin levels were significantly related to low HDL-C and high triglyceride levels and higher insulin and Homeostasis Model Assessment-Estimated Insulin Resistance values were related to high triglyceride and glucose levels. Otunctemur et al. in their study used the Female Sexual Function Index to assess women's sexual function. They clearly showed that sexual dysfunction is more prevalent in pre- and post-menopausal women with metabolic syndrome.
The management of metabolic syndrome in menopausal women should focus mainly on preventive measures along with pharmaceutical treatment wherever necessary. The therapeutic objectives should aim at reducing the underlying causes of metabolic syndrome such as obesity and physical inactivity while treating disease processes such as dyslipidemia, hypertension, and cardiovascular problems.
The following lifestyle modifications should be recommended:
- Moderate physical activity
- Healthy diet with less fats, carbohydrates, and salt
- Giving up smoking and excess alcohol intake
- Intellectual activity.
According to the current data, hormone therapy (HT) is not recommended as a preventive strategy for metabolic disorders in menopause. However, individualization of treatment may often ensure best outcomes. Menopausal HT, particularly estrogen therapy, may be considered to prevent chronic disease after menopause. The use of HT is beneficial overall for reducing many parameters of metabolic syndrome. According to Lobo, in metabolic syndrome, transdermal therapy may be preferable to oral therapy when given in standard doses.
Looking at the altering demographics of India with a trend toward increasing the aging population and changing lifestyle practices, metabolic syndrome will definitely become a significant problem in times to come, affecting not only the postmenopausal women but also the masses in general. Hence, this needs to be addressed seriously and meticulously.
| References|| |
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al.
Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005;112:2735-52.
Gupta A, Gupta R, Sarna M, Rastogi S, Gupta VP, Kothari K, et al.
Prevalence of diabetes, impaired fasting glucose and insulin resistance syndrome in an urban Indian population. Diabetes Res Clin Pract 2003;61:69-76.
Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V. Metabolic syndrome in urban Asian Indian adults – A population study using modified ATP III criteria. Diabetes Res Clin Pract 2003;60:199-204.
Chedraui P, Hidalgo L, Chavez D, Morocho N, Alvarado M, Huc A, et al.
Quality of life among postmenopausal ecuadorian women participating in a metabolic syndrome screening program. Maturitas 2007;56:45-53.
Lobo RA, Davis SR, De Villiers TJ, Gompel A, Henderson VW, Hodis HN, et al.
Prevention of diseases after menopause. Climacteric 2014;17:540-56.
Lobo RA. Metabolic syndrome after menopause and the role of hormones. Maturitas 2008;60:10-8.
Eshtiaghi R, Esteghamati A, Nakhjavani M. Menopause is an independent predictor of metabolic syndrome in Iranian women. Maturitas 2010;65:262-6.
Gaspard U. Hyperinsulinaemia, a key factor of the metabolic syndrome in postmenopausal women. Maturitas 2009;62:362-5.
Chedraui P, Pérez-López FR, Escobar GS, Palla G, Montt-Guevara M, Cecchi E, et al.
Circulating leptin, resistin, adiponectin, visfatin, adipsin and ghrelin levels and insulin resistance in postmenopausal women with and without the metabolic syndrome. Maturitas 2014;79:86-90.
Otunctemur A, Dursun M, Ozbek E, Sahin S, Besiroglu H, Koklu I, et al.
Effect of metabolic syndrome on sexual function in pre- and postmenopausal women. J Sex Marital Ther 2015;41:440-9.
Stachowiak G, Pertyński T, Pertyńska-Marczewska M. Metabolic disorders in menopause. Prz Menopauzalny 2015;14:59-64.
Stachowiak G, Zajac A, Pertynski T. Zespol metaboliczny u kobiet w okresie menopauzy. Prz Menopauzalny 2009;8:6-10.